```html

Muir‑Torre Syndrome (MTS): A Comprehensive Medical Guide

Overview

Muir‑Torre syndrome (MTS) is a rare hereditary cancer‑predisposition syndrome that combines the features of Lynch syndrome (also called hereditary non‑polyposis colorectal cancer, HNPCC) with the development of specific skin tumors, most commonly sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas. The condition is autosomal‑dominant, meaning a single altered copy of a disease‑causing gene is enough to increase cancer risk.

• Who it affects: Both males and females are equally susceptible. Symptoms usually appear in adulthood, but skin lesions can be identified as early as the late teens.
• Prevalence: MTS is extremely uncommon, estimated at 1–2 cases per 100,000 individuals worldwide. It accounts for <1% of all Lynch‑syndrome families.
• Typical age of presentation: Median age for the first skin lesion is 44 years; colorectal cancer often presents a decade earlier than sporadic cases (average 45–50 years vs. 68 years in the general population).

Because MTS is a variant of Lynch syndrome, individuals with MTS have a markedly increased lifetime risk for several internal malignancies, especially colorectal, endometrial, ovarian, urinary tract, and upper gastrointestinal cancers.

Symptoms

Symptoms of MTS can be divided into two categories: cutaneous (skin) findings and internal (visceral) malignancies.

Cutaneous manifestations

• Sebaceous adenoma – Benign, yellow‑tan, often dome‑shaped nodules that arise on the face, scalp, or trunk. They may be painless and grow slowly.
• Sebaceous carcinoma – Malignant lesion that can appear similar to an adenoma but may ulcerate, bleed, or become crusted. Aggressive forms can metastasize.
• Keratoacanthoma – Rapidly growing, dome‑shaped nodule with a central keratin plug; usually resolves spontaneously but can be a harbinger of MTS.
• Other skin tumors – Basal cell carcinoma, squamous cell carcinoma, and atypical melanocytic lesions occur more often in MTS carriers.

Visceral (internal) manifestations

• Colorectal cancer – Usually right‑side colon tumors; may present with change in bowel habits, rectal bleeding, or abdominal pain.
• Endometrial cancer – Abnormal uterine bleeding, pelvic pain, or post‑menopausal spotting.
• Ovarian cancer – Often silent; may cause abdominal bloating, early satiety, or pelvic discomfort.
• Urinary tract cancers (renal pelvis, ureter, bladder) – Hematuria, flank pain, or recurrent urinary infections.
• Gastric and small‑intestinal adenocarcinomas – Nausea, vomiting, weight loss, or anemia.
• Pancreatic cancer – New‑onset diabetes, upper abdominal pain, or jaundice.
• Other rare tumors – Brain, hepatobiliary, and sebaceous gland cancers of the eye.

Causes and Risk Factors

MTS arises from inherited mutations that impair DNA mismatch repair (MMR). The most common genes involved are:

• MLH1 (mutL homolog 1)
• MSH2 (mutS homolog 2)
• MSH6 (mutS homolog 6)
• PMS2 (post‑meiotic segregation increased 2)
• Rarely, mutations in the EPCAM gene that silence MSH2.

These genes normally correct errors that occur when DNA replicates. When they are defective, cells accumulate mutations, greatly increasing cancer risk.

Who is at higher risk?

• First‑degree relatives of an individual with a confirmed pathogenic MMR mutation.
• People with a personal or family history of both sebaceous skin tumors and Lynch‑associated cancers.
• Ethnic background – No specific ethnicity predominates, but the mutation prevalence mirrors that of Lynch syndrome (approximately 1 in 300–500 individuals carries a pathogenic MMR mutation).
• Age – Risk rises sharply after age 30; by age 70, the lifetime risk of colorectal cancer can exceed 80% in untreated carriers.

Diagnosis

Diagnosing MTS requires a combination of clinical assessment, pathology, and genetic testing.

Clinical evaluation

• Detailed personal and three‑generation family history focusing on skin lesions and Lynch‑associated cancers.
• Skin examination by a dermatologist to identify characteristic sebaceous lesions.

Pathology

Biopsy of a skin lesion is essential. Pathologists look for:

• Sebaceous differentiation (presence of lipid‑laden cells).
• Loss of MMR protein expression on immunohistochemistry (IHC) – especially MSH2 and MSH6, which are most frequently absent in MTS.

Genetic testing

DNA sequencing of the MMR genes (MLH1, MSH2, MSH6, PMS2) or EPCAM deletion analysis confirms the diagnosis. Testing is recommended for:

• The affected individual (proband).
• At‑risk relatives once a pathogenic variant is identified.

Results guide surveillance and inform cascade testing for family members.

Additional screening studies

• Colonoscopy – Baseline colonoscopy at age 20–25 (or 2–5 years before the earliest family case) and then every 1–2 years.
• Upper GI endoscopy – Every 3–5 years to detect gastric or duodenal adenomas.
• Transvaginal ultrasound & endometrial biopsy – For women, starting at age 30–35, repeated annually.
• Urinary tract imaging (CT urography or MRI) – Every 3–5 years.
• Dermatologic exam – Every 6–12 months.

Treatment Options

Treatment for MTS is individualized and focuses on two fronts: managing existing tumors and reducing future cancer risk.

Management of skin lesions

• Surgical excision – Preferred for sebaceous carcinoma or suspicious adenomas.
• Mohs micrographic surgery – Offers tissue-sparing removal for facial or cosmetically sensitive sites.
• Topical or intralesional therapies – 5‑fluorouracil or imiquimod may be used for superficial keratoacanthomas.

Management of internal cancers

• Colorectal cancer – Standard colon‑segment resection with adequate lymphadenectomy; consider adjuvant chemotherapy (e.g., 5‑FU/LV, oxaliplatin) per stage.
• Endometrial/ovarian cancer – Total hysterectomy with bilateral salpingo‑oophorectomy; platinum‑based chemotherapy for advanced disease.
• Other malignancies – Management follows organ‑specific oncologic guidelines; many MTS tumors respond similarly to sporadic counterparts.

Pharmacologic prevention

• Aspirin chemoprevention – Low‑dose aspirin (81–325 mg daily) has been shown to reduce colorectal cancer incidence in Lynch‑syndrome carriers (CAPP2 trial). Discuss risks (GI bleeding) with a physician.
• Immune checkpoint inhibitors – Pembrolizumab or nivolumab are FDA‑approved for microsatellite‑instable (MSI‑H) tumors, a hallmark of MMR deficiency.

Lifestyle & supportive measures

• Smoking cessation and limiting alcohol intake (both increase colorectal cancer risk).
• Maintaining a healthy weight (BMI < 25) and regular physical activity (≥150 min moderate exercise per week).
• High‑fiber, low‑red‑meat diet rich in fruits, vegetables, and whole grains.

Living with Muir‑Torre Syndrome

While a diagnosis of MTS can be overwhelming, proactive management dramatically improves outcomes.

Practical daily‑management tips

1. Maintain a detailed health journal – Note new skin lesions, changes in bowel habits, menstrual irregularities, or urinary symptoms.
2. Schedule and attend all recommended screenings – Use calendar reminders or a patient‑portal to keep appointments.
3. Engage a multidisciplinary care team – Include a gastroenterologist, dermatologist, genetic counselor, and, when needed, a gynecologic oncologist.
4. Utilize genetic counseling – Understand inheritance patterns, discuss family planning, and arrange cascade testing for relatives.
5. Seek psychosocial support – Counseling, support groups, or patient organizations (e.g., *Lynch Syndrome International*) can help cope with anxiety.
6. Practice sun protection – Although MTS lesions are not UV‑driven, protecting skin reduces the background risk of other skin cancers.

Family planning considerations

Because MTS follows an autosomal‑dominant pattern, each child of a carrier has a 50% chance of inheriting the mutation. Options to discuss with a genetic counselor include:

• Pre‑implantation genetic testing (PGT‑M) with IVF.
• Prenatal testing ( CVS or amniocentesis) if pregnancy occurs naturally.
• Adoption or use of donor gametes.

Prevention

True primary prevention (eliminating the genetic defect) isn’t possible, but risk reduction strategies are effective.

• Regular surveillance – Early detection of cancer dramatically improves cure rates.
• Aspirin chemoprevention – As noted, low‑dose aspirin reduces colorectal neoplasia in Lynch carriers.
• Vaccination – Hepatitis B vaccine to lower liver cancer risk; HPV vaccine to protect against cervical and oropharyngeal cancers, which may be slightly elevated.
• Environmental modifications – Avoid known carcinogens (tobacco, excessive alcohol, occupational exposures).

Complications

If MTS is left untreated or inadequately surveilled, patients face several serious complications:

• Advanced colorectal cancer – May lead to bowel obstruction, perforation, or metastasis (liver, lung).
• Metastatic sebaceous carcinoma – Can spread to regional lymph nodes, lung, or brain.
• Fertility issues – Hysterectomy or oophorectomy for gynecologic cancers may affect fertility; early discussion of fertility preservation is essential.
• Psychological burden – Chronic anxiety, depression, or “cancer‑fatigue” from repeated procedures.
• Secondary malignancies – Radiation therapy for certain cancers can increase the risk of future neoplasms.

When to Seek Emergency Care

Key References

• Mayo Clinic. Lynch syndrome. Updated 2023.
• National Cancer Institute. Hereditary non‑polyposis colorectal cancer (Lynch syndrome) Fact Sheet. 2022.
• World Health Organization. Hereditary cancer syndromes. 2021.
• J. Jass et al. “Muir‑Torre syndrome: clinicopathologic and molecular features.” *J Pathol* 2020; 251(2): 115‑124.
• Barrow et al. “Aspirin for cancer prevention in Lynch syndrome (CAPP2): long‑term follow‑up.” *Lancet Oncology* 2021; 22(9): 1245‑1255.
• Cleveland Clinic. Muir‑Torre Syndrome. Accessed May 2026.

```